Le Lézard
Classified in: Health
Subject: ACC

Royal DSM - Repurchase of Shares (15 ? 18 April 2019)


HEERLEN, Netherlands, April 23, 2019 /PRNewswire/ --

Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, has repurchased 123,006 of its own shares in the period from 15 April 2019 up to and including 18 April 2019 at an average price of ?102.40. This is in accordance with the repurchase announced on 14 March 2019, covering the intended reduction of issued capital as well as commitments under share-based compensation plans and for stock dividends. The consideration of this repurchase was ?12.6 million.  

     (Logo: https://mma.prnewswire.com/media/657851/DSM_Logo.jpg )

The total number of shares repurchased under this program to date is 496,708 shares for a total consideration of ?50.3 million.

For more detailed information see 'Daily transaction details Share Repurchase Program announced 14 March 2019'.

DSM - Bright Science. Brighter Living.tm 

Royal DSM is a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living. DSM's purpose is to create brighter lives for all. DSM addresses, with its products and solutions, some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders - customers, employees, shareholders, and society at large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about ?10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com.

 

    PRN NLD

 


These press releases may also interest you

at 07:10
Science Corporation ("Science"), a leader in brain-computer interface ("BCI") technology and the developer of the Science Eye, has acquired the IP and related assets for the PRIMA retinal implant, developed by Pixium Vision SA ("Pixium") of France, a...

at 07:05
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...

at 07:05
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...



News published on and distributed by: